Scientists and vaccine developers involved in EVI projects presented project progress and research findings, highlighting one of the most important areas of EVI's activities;
translation of research on diseases of poverty vaccines, focusing on
early stages from preclinical to
clinical development through harmonisation.
Despite ongoing efforts toward finding novel entities for the treatment of the most challenging cancers,
translation into patient benefit has been slow due to the fact that translational cancer research from
early drug discovery to late stage drug development and assessment in
clinical trials is a long process.